• Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs • New brand reinforces Apollomics’ mission to discover and develop novel medicines and effective combination therapies to improve the lives of cancer patients FOSTER CITY, Calif. and HANGZHOU, China, January 7, 2019-- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced it has raised $100 million in a Series B financing. The financing is led by CMB International (“CMBI”), a subsidiary of China Merchants Bank, with participation from existing Series A investor OrbiMed Asia, and several new investors.